<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464594</url>
  </required_header>
  <id_info>
    <org_study_id>JEDIS ver.4.0</org_study_id>
    <secondary_id>UMIN000000681</secondary_id>
    <nct_id>NCT00464594</nct_id>
  </id_info>
  <brief_title>Japan Early Diabetes Intervention Study</brief_title>
  <acronym>JEDIS</acronym>
  <official_title>A Randomized Comparative Clinical Study on Suppression of Progression From Early Diabetes, Diet/Exercise Standard Intervention vs. Concurrent Pharmacological Standard Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Early Diabetes Intervention Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Early Diabetes Intervention Study Group</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the suppressive effect of two kinds of interventions
      on the worsening/progression to definite diabetes: standard lifestyle guidance and standard
      lifestyle guidance combined with pharmacological intervention (monotherapy with one of
      acarbose, metformin, or gliclazide).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In newly-diagnosed early diabetes patients, a randomized comparative study will be conducted
      to compare the suppressive effect of the following two kinds of interventions on the
      worsening/progression to definite diabetes which has a harmful hyperglycemia i.e. an
      increased risk of microangiopathy: standard education for the improvement of lifestyle in
      accordance with the “Guidelines for the Treatment of Diabetes Mellitus in Japan” of the Japan
      Diabetes Society (JDS) and standard lifestyle guidance combined with pharmacological
      intervention using the lowest possible dose of commercially available oral hypoglycemic
      agents (one of acarbose, metformin, or gliclazide) in Japan.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FPG &gt;= 140mg/dl and HbA1c &gt;= 7.0%</measure>
  </primary_outcome>
  <enrollment>2560</enrollment>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard lifestyle guidance</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifestyle guidance and monotherapy with acarbose</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifestyle guidance and monotherapy with metformin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifestyle guidance and monotherapy with gliclazide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Results of 75-g oral glucose tolerance test (75 g OGTT)will be used to confirm FPG &lt;=
             125 mg/dL, 2-h PG &gt;= 200 mg/dL and HbA1c &lt;= 6.9%

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Undergoing treatment with steroids

          -  Secondary diabetes mellitus

          -  Diabetes mellitus due to suspected gene abnormalities

          -  BMI &gt;= 35 kg/m2 or BMI &lt; 18.5 kg/m2

          -  Undergone a surgery

          -  Severe hyperuricemia (gout) associated with organ dysfunction

          -  Severe vascular diseases with organ dysfunction

          -  Cancer or other malignant neoplasms

          -  Liver cirrhosis or chronic hepatic, chronic renal failure

          -  Gastrointestinal disorders

          -  Always performing rigorous muscular exercise

          -  Severe infection or serious trauma

          -  Women who are pregnant

          -  Alcohol dependence or drug dependence

          -  Drug allergy

          -  Anemic

          -  Abnormal hemoglobinuria

          -  Severe mental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kuzuya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jichi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kazuo Ichikawa</last_name>
    <phone>81-3-3814-8010</phone>
    <email>info@jedis2560.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>03-3813-6111</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2007</study_first_posted>
  <last_update_submitted>April 22, 2007</last_update_submitted>
  <last_update_submitted_qc>April 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2007</last_update_posted>
  <keyword>Japan Early Diabetes Intervention Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

